What Researchers, Sponsors, and Institutions Should Know
In March 2026, the National Institutes of Health (NIH) released two draft resources to improve the design, conduct, and communication with participants in implantable device trials. NIH now requests input from the research community to help shape expectations around post‑trial care and informed consent.
These drafts show growing awareness that implantable device trials pose unique challenges that persist beyond the study.
Why Implantable Device Trials Are Different
Unlike drug studies or short‑term device trials, implantable device research may result in a device that:
- Remains in a participant’s body long after study completion
- Requires ongoing maintenance (e.g., batteries, software updates, repairs)
- Carries ongoing medical, psychosocial, or financial risks
- Depends on proprietary hardware, software, or specialized expertise
- May be difficult or unsafe to remove
NIH’s draft resources acknowledge a key reality: clinical trials may end, but participants’ needs often do not.
Resource 1: Planning for Post‑Trial Care Needs
“Considerations in Planning for the Post‑Trial Needs of Research Participants Who Receive an Investigational Implantable Device”
This resource offers a planning framework for post‑trial care in implantable device studies. While voluntary, it sets expectations for participant‑centered trial design.
Key Highlights
1. Post‑Trial Planning Should Start Before Enrollment – NIH advises making post‑trial care planning part of trial design. Early planning ensures:
- Continuity of care
- Realistic budgeting and resource allocation
- Meaningful informed consent
2. Clear Decisions About Explantation vs. Retention – Investigators are encouraged to explicitly describe whether a device will:
- Be fully or partially explanted.
- Remain in place after trial completion.
- Be deactivated or remain functional.
Decision‑making should consider participant preferences, safety, clinical benefit, and feasibility.
3. Individual Benefit Matters – One of the most notable ethical positions in the draft:
- If a participant experiences meaningful benefit without safety concerns, they should generally be offered the option to keep the device, unless there is clear justification to the contrary, even if the trial results are not favorable.
4. Long‑Term Needs Extend Beyond Surgery – Post‑trial needs may include:
- Ongoing monitoring and follow‑up
- Device maintenance, repair, or replacement
- Access to compatible hardware and software
- Psychosocial support
- Implications for future care (e.g., MRI compatibility, eligibility for other implants)
5. Transparency Around Financial Responsibility – NIH is explicit that:
- Grant funds cannot be used after the award period ends.
- Insurance coverage is often uncertain.
- Financial responsibility may be shared among investigators, institutions, sponsors, manufacturers, and participants.
Post‑trial plans should clearly state who is responsible for which costs, for how long, and within what limits, including foreseeable out‑of‑pocket costs.
6. Oversight Does Not End With the Trial – Long‑term care plans should include:
- Defined oversight
- Ongoing monitoring
- A named responsible party for implementation and compliance
Resource 2: Strengthening Informed Consent for Implantable Device Research
“Informed Consent for Research Using Investigational Implantable Devices: Points to Consider & Sample Language”
This resource explains how to communicate implant‑specific risks, benefits, and long‑term realities to participants. It includes points to consider and sample language for informed consent.
Key Highlights
1. Enhanced Transparency Is Central – NIH stresses that participants should understand:
- Whether a device will be removed or remain in place
- What happens at the study end or upon withdrawal
- What care, support, or costs may follow
This includes clearly explaining scenarios where a device cannot be safely removed or may become non‑functional after the study.
2. Plain‑Language Expectations – Sample language is designed to be understandable at approximately an 8th‑grade reading level, encouraging:
- Clear headers and short sentences
- Definitions of technical terms
- Supplemental comprehension strategies (e.g., teach‑back)
3. Risks Go Beyond the Operating Room – Consent discussions should address:
- Implantation and explantation risks
- Long‑term physical and psychological risks
- Impact on future medical care or research eligibility
- Risks associated with device maintenance or user error
4. Realistic Discussion of Benefits – NIH emphasizes that consent forms should:
- Describe only direct potential benefits.
- Clearly state that any benefit may be temporary.
- Avoid implying guaranteed or long‑term benefit.
5. Costs Must Be Addressed Head‑On – The draft encourages a clear explanation of:
- Costs incurred during the study
- Likely post‑trial costs if the device remains implanted
- Insurance uncertainty, particularly for unapproved devices
- Whether post‑trial care arrangements exist or not.
Participants should understand financial implications before enrollment.
6. Long‑Term Practical Considerations – Unusually for consent guidance, the resource highlights practical, real‑world issues such as:
- Activity restrictions
- MRI or other equipment limitations
- Device maintenance responsibilities
- Carrying a device information card
- Who to contact for device‑related issues after the study ends
Why NIH Is Seeking Comment Now
Though voluntary, these resources signal NIH’s evolving expectations for responsibility, transparency, and long‑term planning in implantable device research.
Public comments can help NIH:
- Refine feasibility and clarity.
- Identify operational challenges.
- Balance ethical goals with real‑world constraints.
- Ensure the guidance reflects diverse trial settings.
How to Submit Comments
NIH welcomes public comment on both resources. Stakeholders might wish to comment on:
- The practicality of post‑trial care planning expectations
- Financial and operational implications for institutions and sponsors
- Clarity and usability of the consent considerations and sample language
- Areas requiring additional guidance or flexibility
Final Takeaway
Implantable device trials raise questions that extend well beyond study endpoints. NIH’s draft resources squarely acknowledge this reality and encourage a more participant‑centered, transparent, and forward‑looking approach to both trial planning and informed consent.
Take action now: submit your comments to NIH and help ensure the guidance addresses real-world needs. Your input can shape how implantable device trials are designed and conducted for years to come.
